A European BIO bank
to decipher the missing
heritability of neurodegenerative diseases.
EADB
Our history,
EADB
The European Alzheimer & Dementia Biobank (EAD) was created in 2017 thanks to an EU Joint Programme – Neurodegenerative Disease Research (JPND). Its initial aim was to carry out the world’s largest GWAS study on the risk of developing Alzheimer’s disease, collecting new DNA samples from 14 European countries and bringing together the existing GWAS European consortia.
The consortium has since expanded to 18 countries and is also interested iin the genetics of the conversion from cases suffering from mild cognitive impairment to dementia, the genetics of vascular dementia and the genetics of Alzheimer’s disease biomarkers.
The consortium is also generating a large amount of high-throughput sequencing data and is interested in generating and combining biomarker and proteomic data
Participating countries
Data
Genotyping
Different summary statistics available.
Acces to raw data and imputed data availble upon request
Sequencing
Different summary statistics available.
Acces to raw data available upon request and through the Alzheimer’s Disease Genetics Hub
Biomarkers
Numerous biomarkers quantified in plasma and/or CSF.
Raw data and samples avaible upon request
Collaboration
Collaborate
Together
EADB believes it is essential to encourage collaboration to improve our knowledge of Alzheimer’s disease and related disorders. The EADB and its partners welcome all types of collaborations on genetics and biomarkers.
Please do not hesitate to contact us.
